rt_PA静脉溶栓治疗急性脑梗死的临床研究
2015-01-20贺利峰等
贺利峰等
[摘要]目的探讨重组组织型纤溶酶原激活物(rt_PA)静脉溶栓治疗急性脑梗死的临床疗效。方法69例发病在4.5小时内具有溶栓指征的急性脑梗死患者,其中观察组37例行rt_PA静脉溶栓,对照组32例行常规抗血小板治疗。以美国国立卫生院卒中量表(NIHSS)评分评定溶栓后临床疗效,以Barthel指数(BI)评分及改良Rankin量表(mRS)评分判断治疗后90d生活质量及预后。结果观察组治疗后2h、24h、7d NIHSS评分显著低于对照组[(9.23±3.51)vs(11.32±1.12),(6.72±2.31)vs(9.24±2.53),(4.23±2.12)vs(7.34±1.43)],差异有统计学意义(P<0.05);治疗后90天BI评分观察组显著高于对照组[(78.56±3.51)vs(61.30±4.13)],差异有统计学意义(P<0.05);治疗后90天mRS评分疗效良好率观察组显著高于对照组[67.56%(25/37)vs 34.38%(11/32)],差异有统计学意义(P<0.01)。观察组24h脑出血率及死亡率高于对照组[16.21%(6/37)vs 9.37%(3/32)],但差异无统计学意义(P>0.05)。结论时间窗内rt_PA静脉溶栓治疗急性脑梗死近、远期疗效均较常规抗血小板治疗显著。
[关键词]急性脑梗死;静脉溶栓;重组组织型纤溶酶原激活物
中图分类号:R743.3文献标识码:A文章编号:1009_816X(2014)06_0468_03
[Abstract] Objective To investigate the clinical effects of rt_PA intravenous thrombolysis therapy on acute ischemic stroke. Methods Since January to December in 2010, The Neurology Department of Huzhou center hospital received and cured 69 patients in 4.5 hours after the onset of acute ischemic stroke who have thrombolysis indication and sign the treatment consent form. The 37 cases in treatment group received rt_PA intravenous thrombolysis therapy, while 32 cases in control group received routine antiplatelet therapy. The United States national institutes of health stroke scale (NIHSS) was used to evaluate the clinical effects after thrombolysis. Barthel index (BI) and Modified Rankin scale (mRS) were used to judge quality of life and prognosis after treatment for 90 days. Results NHISS scores of treatment group were significantly lower than the control group after treatment for 2h, 24h and 7d [(9.23±3.51) versus (11.32±1.12), (6.72±2.31) versus (9.24±2.53), (4.23±2.12) versus (7.34±1.43)], there were statistical significance differences (P<0.05); BI score of treatment group was significantly higher than control group after treatment for 90 days [(78.56±3.51) versus (61.30±4.13)], there was a statistical significance difference (P<0.05); Good Effect rate of mRS score of treatment group was significantly higher than the control group after treatment for 90 days [67.56%(25/37) versus 34.38%(11/32)], there was a statistical significance difference (P<0.05). Cerebral hemorrhage rate after 24h in treatment group was higher than the control group [16.21%(6/37) versus 9.37%(3/32)], there were no statistical significance (P>0.05). Conclusions The short and long term curative effects of rt_PA intravenous thrombolysis treatment within the time window on acute cerebral infarction are significantly better than conventional antiplatelet therapy, but the risk of hemorrhage is higher.endprint
[Key words] Acute ischemic stroke; Intravenous thrombolysis; rt_PA
早期再通血管恢复脑血流是治疗急性脑梗死的关键环节。临床研究表明,时间窗内应用重组组织型纤溶酶原激活剂(rt_PA)静脉溶栓治疗急性脑梗死,疗效确切,不良反应发生率低。本文回顾性研究发病在4.5小时内的具有溶栓指征的急性脑梗死患者,比较静脉溶栓与常规抗血小板治疗的近、远期疗效及安全性差异。
1资料与方法
1.1一般资料:选取2010年1月至2012年12月入住我院69例急性脑梗死患者,均符合第四届全国脑血管病学术会议制定的诊断标准。入选标准:参照2010年《中国脑血管病防治指南》[1],年龄18~80岁;临床症状符合缺血性脑血管病的诊断标准,发病时间在4.5h以内;美国国立卫生院卒中量表(NIHSS)评分4~24分之间,症状持续1h以上,神经功能缺失情况无明显改善;脑CT排除颅内出血,且无早期大面积脑梗死影像学改变;……
